WT1 and chronic myelogenous leukemia, BCR-ABL1 positive: The results demonstrated that the novel and chemically synthesized antagonistic peptide WIP2W can specifically bind to the intracellular WT1 protein, and its micellar formulation (M—WIP2W) can significantly enhance cell death and inhibit the tumor growth of WT1+ BP-CML mice.